Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1085-1092

  Baba, Michihiro ^a   Castillo, Andres ^a   Koriyama, Chihaya ^a   Yanagi, Masakazu ^a   Matsumoto, Hidehiko ^a   Natsugoe, Shoji ^a   Shuyama, Karem Y ^a   Khan, Noureen ^a   Higashi, Michiyo ^a   Itoh, Tetsuhiko ^b   Eizuru, Yoshito ^b   Aikou, Takashi ^a   Akiba, Suminori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kodama Hospital   (Japan)

Author keywords

Adenocarcinoma; Gefitinib; Human papillomavirus; Lung

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GEFITINIB; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENOME; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; JAPAN; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VIRUS DETECTION; VIRUS LOAD;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; QUINAZOLINES; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949468394     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000736     Document Type: Article

References (43)

1. Klein F, Amin Kotb WF and Petersen I: Incidence of human papillomavirus in lung cancer. Lung Cancer 65: 13-18, 2009.
2. Syrjanen KJ: HPV infections and lung cancer. J Clin Pathol 55: 885-891, 2002.
3. Miyagi J, Tsuhako K, Kinjo T, Iwamasa T and Hirayasu T: Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung I Okinawa, a subtropical island in southern Japan. J Clin Pathol 53: 676-684, 2000.
4. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, Su JM and Lee H: The association of human papillomavirus 16/18 infection with lung cancer among non-smoking Taiwanese women. Cancer Res 61: 2799-2803, 2001.
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
6. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V and Heelan RT: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109, 2004.
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
9. Bosch FX, Lorincz A, Munoz N, Meijer C and Shah KV: The causal relationship between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265, 2002.
10. IARC: Monographs on the evaluation of carcinogenic risks to humans. In: Human Papillomaviruses. Vol 90. International Agency for Research on Cancer, Lyon, 2007.
11. Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E and Czerwenka KF: Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 92: 873-880, 2004.
12. Aguayo F, Castillo A, Koriyama C, Higashi M, Itoh T, Capetillo M, Shuyama K, Corvalan A, Eizuru Y and Akiba S: Human papillomavirus-16 is integrated in lung carcinomas: a study in Chile. Br J Cancer 97: 85-91, 2007.
13. Arias-Pulido H, Peyton CL, Joste NE, Vargas H and Wheeler CM: Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 44: 1755-1762, 2006.
14. Hoppe-Seyler F and Butz K: Cellular control of human papillomavirus oncogene transcription. Mol Carcinog 10: 134-141, 1994.
15. Barbosa MS: The oncogenic role of human papillomavirus proteins. Crit Rev Oncog 7: 1-18, 1996.
16. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY and Lee H: Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 67: 10686-10693, 2007.
17. Fiedler M, Muller-Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen-Durr P and Zwerschke W: High level HPV16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J 18: 1120-1122, 2004.
18. Khleif SN, De Gregori J, Yee C, Otterson GA, Kaye FJ, Nevins JR and Howley PM: Inhibition of cyclin D-CDK4/ CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93: 4350-4354, 1996.
19. Sano T, Oyama T, Kashiwabara K, Fukuda T and Nakajima T: Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153: 1741-1748, 1998.
20. Peitsaro P, Johansson B and Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886-891, 2002.
21. The Japan Lung Cancer Society: Classification of Lung Cancer. 1st edition. Kanehara & Co., Ltd., Tokyo, pp54-65, 2000.
22. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B and Quint W: Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153: 1731-1739, 1998.
23. Kleter B, van Doorn LJ, Schrauwen L, Molijin A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M and Quint W: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517, 1999.
24. Ralhan R, Mathew R, Arora S, Bahl R, Shukla NK and Mathur M: Frequent alterations in the expression of tumor suppressor genes p16INK4A and pRb in esophageal squamous cell carcinoma in the Indian population. J Cancer Res Clin Oncol 126: 655-660, 2000.
25. Xu H, Lu DW, El-Mofty SK and Wang HL: Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papilomas: association with human papillomavirus 11 and lack of aberrant p53, Rb and p16 protein expression. Hum Pathol 35: 1419-1422, 2004.
26. Skinner GR: Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: evidence for a 'hit and run' mechanism. Br J Exp Pathol 57: 361-376, 1976.
27. Smith KT and Campo MS: 'Hit and run' transformation of mouse C127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology 164: 39-47, 1988.
28. Iwasaka T, Hayashi Y, Yokoyama M, Hara K, Matsuo N and Sugimori H: 'Hit and run' oncogenesis by human papillomavirus type 18 DNA. Acta Obstet Gynecol Scand 71: 219-223, 1992.
29. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A and von Knebel Doeberitz M: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68: 307-313, 2008.
30. Masuda A and Takahashi T: Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 21: 6884-6897, 2002.
31. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
32. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T and Takahashi T: Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 24: 1679-1688, 2006.
33. Tsai TC and Chen SL: The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch Virol 148: 1445-1453, 2003.
34. Zur Hausen H: Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. Lancet 343: 955-957, 1994.
35. Linardou H, Dahabreh I, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA and Murray S: Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9: 962-972, 2008.
36. Noutsou A, Koffa M, Ergazaki M, Siafakas NM and Spandidos DA: Detection of human papillomavirus (HPV) and K-ras mutations in human lung carcinomas. Int J Oncol 8: 1089-1093, 1996.
37. Cheng YW, Chiou HL, Chen JT, Chou MC, Lin TS, Lai WW, Chen CY, Tsai YY and Lee H: Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan. Lung Cancer 46: 165-170, 2004.
38. Weber W, De Sabata MS, Paredes RM, Rodriguez G, Santos C, Sabillon JU and Zwahlen M: Cancer in first degree relatives of Latin American women with cervical cancer: a pilot study. Anticancer Res 25: 1219-1223, 2005.
39. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH and Turek LP: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108: 766-772, 2004.
40. Jeon S, Allen-Hoffmann BL and Lambert PF: Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 69: 2989-2997, 1995.
41. Vernon SD, Unger ER, Miller DL, Lee DR and Reeves WC: Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer 74: 50-56, 1997.
42. Eriksson A, Herron JR, Yamada T and Wheeler CM: Human papillomavirus type 16 variant lineage characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. J Gen Virol 80 (Pt3): 595-600, 1999.
43. Ruutu MP, Kulmala SM, Peitsaro P and Syrjanen SM: The performance of the HPV16 real-time PCR integration assay. Clin Biochem 41: 423-428, 2008.